Clinical Trials
111 trialsNCT05498220 2026-04-16
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT05537766 2026-03-10
ZUMA-25
Gilead Sciences
Phase 2 Terminated
NCT03211988 2026-03-02
Entinostat Neuroendocrine (NE) Tumor
Columbia University
Phase 2 Terminated
NCT05714345 2026-03-02
EXPAND
Allogene Therapeutics
Phase 2 Terminated
NCT04268277 2026-02-27
Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
University of Ulm
Phase 2 Terminated
NCT06865677 2026-01-21
Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT03993379 2025-12-26
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
CytomX Therapeutics
Phase 2 Terminated
NCT05263492 2025-10-02
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
Virginia Commonwealth University
Phase 2 Terminated
NCT05883449 2025-08-20
LuminICE-203
Affimed GmbH
Phase 2 Terminated
NCT05972720 2025-05-15
FIRCE-1
CARGO Therapeutics
Phase 2 Terminated
NCT05275673 2025-04-24
A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer
Faeth Therapeutics
Phase 2 Terminated
NCT03683277 2025-02-19
IFM2014-01
Intergroupe Francophone du Myelome
Phase 2 Terminated
NCT04342962 2025-01-30
Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Terminated
NCT03891576 2025-01-17
Newton
Mario Negri Institute for Pharmacological Research
Phase 2 Terminated
NCT01032070 2024-12-12
PETEY
Astellas Pharma Inc
Phase 2 Terminated
NCT04129151 2024-08-01
Palbociclib + Ganitumab In Ewing Sarcoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT03439085 2024-07-09
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03969420 2023-11-09
Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy
Sumitomo Pharma America, Inc.
Phase 2 Terminated
NCT02294357 2023-11-01
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
Oncotherapeutics
Phase 2 Terminated
NCT03679624 2023-10-23
Daratumumab Plus Ibrutinib in Patients With WaldenstrÓ§m's Macroglobulinemia
Weill Medical College of Cornell University
Phase 2 Terminated
NCT03805841 2023-06-28
RAIN
Rain Oncology Inc
Phase 2 Terminated
NCT03713944 2023-03-01
Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
Big Ten Cancer Research Consortium
Phase 2 Terminated
NCT02807454 2023-02-21
FUSIONMM-003
Celgene
Phase 2 Terminated
NCT03422523 2022-08-22
ARGO
University Hospital Southampton NHS Foundation Trust
Phase 2 Terminated
NCT00464178 2022-07-20
A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Hackensack Meridian Health
Phase 2 Terminated
NCT03077698 2022-06-07
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
Xenetic Biosciences, Inc.
Phase 2 Terminated
NCT03063203 2022-06-02
Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia
Washington University School of Medicine
Phase 2 Terminated
NCT04525391 2022-02-25
SUKSES-N5
Samsung Medical Center
Phase 2 Terminated
NCT01606566 2022-02-18
A Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin for Recurrent Head and Neck Cancer.
PCI Biotech AS
Phase 2 Terminated
NCT01158885 2021-10-26
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2 Terminated
NCT03795012 2021-08-31
Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients
MedSIR
Phase 2 Terminated
NCT03567616 2021-06-30
A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
Phase 2 Terminated
NCT02514252 2021-05-18
Sublingual Fentanyl for the Management of Breakthrough Pain
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01876043 2021-01-25
APLIPO
Institut Bergonié
Phase 2 Terminated
NCT03465891 2021-01-12
Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT03512353 2021-01-08
A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
Amgen
Phase 2 Terminated
NCT03887442 2021-01-07
EXTAX
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Phase 2 Terminated
NCT02952573 2020-09-17
Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement
University Health Network, Toronto
Phase 2 Terminated
NCT02147990 2020-08-12
NSCLC
Clovis Oncology, Inc.
Phase 2 Terminated
NCT00939653 2020-02-19
T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2 Terminated
NCT00752206 2020-01-18
A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung
Sarcoma Alliance for Research through Collaboration
Phase 2 Terminated
NCT03120676 2019-11-14
Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT00408252 2019-09-19
Efficacy of SU 011248 in Head And Neck Carcinoma
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Terminated
NCT02789189 2019-09-06
Nedaplatin Combined With Gemcitabine in the Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma : a Single Arm and Phase â…¡ Clinical Trail
Sun Yat-sen University
Phase 2 Terminated
NCT02535806 2019-08-13
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
Children's Mercy Hospital Kansas City
Phase 2 Terminated
NCT02042950 2019-05-01
A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01420081 2019-01-08
A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer
Pfizer
Phase 2 Terminated
NCT01235793 2018-11-20
DRBEAT
Cedars-Sinai Medical Center
Phase 2 Terminated
NCT00847223 2018-08-23
Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma
Lymphoma Study Association
Phase 2 Terminated
NCT01852292 2018-07-24
Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy
Novartis
Phase 2 Terminated